Biotech Firm Cellino Launches Immune Cell Storage Service

The company’s new subsidiary, Reservoir, now offers long-term cryopreservation of immune cells for consumers.

Updated on Oct. 15, 2026 in Biotech

Biotech Firm Cellino Launches Immune Cell Storage Service

Live Poll

Would you pay to store your immune cells in hopes of future medical benefit?

Biotech startup Cellino has launched a new service called Reservoir that allows individuals to store their immune cells at a specialized facility. The company aims to provide consumers with future health options that may leverage advancements in medical science.

Why it matters

This service provides an option for individuals who may require cells for future treatments, such as those undergoing chemotherapy or immunosuppressive therapies. The offering also targets longevity enthusiasts interested in banking biological material for potential use as technology evolves.

The storage process costs $5,000 for the initial blood draw and preservation, followed by a $270 annual maintenance fee. Samples are kept at a temperature of negative 150 degrees Celsius at a secure facility located in the Midwest.

The players

Cellino

This biotechnology startup focuses on cell-based medicine and has secured $96 million in total venture funding.

Reservoir

This subsidiary of Cellino manages the company's new immune cell storage service for consumers.

Advanced Research Projects Agency for Health

This federal agency, known as ARPA-H, holds a $25 million contract with Cellino for health technology development.

The details

Reservoir, a subsidiary of Cellino, handles the separation of immune cells from blood samples before they are transported to the storage facility. Access to the preserved cells requires specific client instructions and official signoff from a physician.

October 15, 2026: Cellino officially launched the Reservoir storage service.
2022: Cellino reached a $140 million valuation following an equity raise.
2019: The company's cofounders were named to the Forbes 30 Under 30 list.
2017: Cellino was established by its cofounders.

The Tech Race

This venture represents a move to commercialize bio-banking infrastructure, mirroring broader industry efforts to move from research-only storage to direct-to-consumer health services. It shifts the competitive landscape by positioning startup-led cryopreservation as a viable consumer market.

The service is currently available to residents in San Francisco, Los Angeles, Miami, and New York. Potential customers should note that this storage option is not covered by insurance and requires a physician’s signoff to release the cells.

The takeaway

Interested consumers should carefully evaluate the medical necessity of cell storage before committing to the ongoing annual fees. While the technology offers a potential hedge against future health needs, it currently remains an experimental and private-pay financial investment.